益气化瘀解毒汤联合干扰素治疗宫颈高危型人乳头瘤病毒持续感染  

Treatment of Yiqi Huayu Jiedu Decoction Combined with Interferon in Treating Persistent High-risk Human Papillomavirus Infection in Cervix

作　　者：李姗[1] 张娥[1] 王丽娜[1] 范家英[2] LI Shan;ZHANG E;WANG Lina;FAN Jiaying(The First Affiliated Hospital to Henan University of Chinese Medicine,Zhengzhou Henan China 450000;Henan University of Chinese Medicine,Zhengzhou Henan China 450046)

机构地区：[1]河南中医药大学第一附属医院,河南郑州450000 [2]河南中医药大学,河南郑州450046

出　　处：《中医学报》2025年第5期1121-1126,共6页Acta Chinese Medicine

基　　金：河南省中医药科学研究专项课题项目(2022JDZX054)。

摘　　要：目的:探讨益气化瘀解毒汤联合干扰素治疗宫颈高危型人乳头瘤病毒(high risk human papllimavirus,HR-HPV)持续感染的临床疗效。方法:86例宫颈HR-HPV持续感染患者按照随机数字表法平行随机分为对照组和研究组。对照组给予重组人干扰素α-2b凝胶,研究组在对照组治疗基础上给予益气化瘀解毒汤。比较两组中医证候积分、阴道微环境生态指标、HPV转阴情况、T细胞亚群及临床疗效。结果:(1)治疗后,研究组有效率为93.02%(40/43),对照组有效率为76.74%,两组有效率比较,差异有统计学意义(P<0.05)。(2)治疗后,两组患者中医证候积分均低于本组治疗前(P<0.05);研究组中医证候积分为(4.02±3.41)分,低于同期对照组(P<0.05)。(3)治疗后,研究组患者阴道清洁度中Ⅰ-Ⅱ度的患者占95.35%,pH值≤4.5的患者占90.70%,过氧化氢阴性患者占83.72%,白细胞酯酶阴性患者占86.05%,均明显高于同期对照组(P<0.05)。(4)治疗后第6个月,研究组HPV转阴率为86.05%,显著高于同期对照组(P<0.05)。(5)治疗后,两组HR-HPV感染患者的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)显著高于治疗前(P<0.05),CD8^(+)显著下降(P<0.05);研究组HR-HPV感染患者的CD3^(+)为(62.74±2.71)%、CD4^(+)为(37.11±2.35)%、CD4^(+)/CD8^(+)为(1.76±0.12),均高于同期对照组(P<0.05);CD8^(+)为(21.07±1.46)%,低于同期对照组(P<0.05)。(6)安全性评价:两组患者均无不良事件发生。结论:益气化瘀解毒汤联合重组人干扰素α-2b凝胶治疗宫颈HR-HPV持续感染疗效显著,可有效改善中医证候,调节免疫功能,改善阴道微环境生态指标,提升HPV转阴率,降低复发风险。Objective:To investigate the clinical efficacy of Yiqi Huayu Jiedu Decoction combined with interferon in treatment of persistent cervical high-risk human papllimavirus(HR-HPV)infection.Methods:Eighty-six patients with persistent cervical HR-HPV infection were randomly divided into the control group and the study group according to the method of randomized numerical table.The control group was given recombinant human interferonα-2b gel,and the study group was given Yiqi Huayu Jiedu Decoction based on the treatment in the control group.The two groups were compared in terms of TCM evidence points,ecological indexes of vaginal microenvironment,HPV conversion,T-cell subpopulations and clinical efficacy.Results:(1)After treatment,the effective rate of the study group was 93.02%(40/43),and the effective rate of the control group was 76.74%.The difference of the efficiency of the two groups was statistically significant(P<0.05).(2)After treatment,the TCM evidence points of patients in both groups were significantly lower than those before treatment in this group(P<0.05);the TCM evidence points of the research group were(4.02±3.41),which were significantly lower than those of the control group in the same period(P<0.05).(3)After treatment,95.35%of the patients in the study group had vaginal cleanliness of I-II degree,90.70%of the patients had pH≤4.5,83.72%of the patients had negative hydrogen peroxide,and 86.05%of the patients had negative leukocyte lipase,all of which were significantly higher than those in the same period of time in the control group(P<0.05).(4)At the 6th month after treatment,the HPV conversion rate of the study group was 86.05%,which was significantly higher than that of the control group in the same period(P<0.05).(5)After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)of HR-HPV-infected patients in the two groups were significantly higher than those before treatment(P<0.05),and the levels of CD8^(+)were significantly lower(P<0.05);(5)After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/

关 键 词：宫颈高危型人乳头瘤病毒持续感染 益气化瘀解毒汤 重组人干扰素Α-2B凝胶 中医证候 阴道微生态 

分 类 号：R271.911.74[医药卫生—中西医结合]